TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11869725

Group type: EXPERIMENTAL
Intervention: Fodor's variant of the Wason selection task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original Wason selection task
Number of subjects: 0
Study: 10659374

Group type: EXPERIMENTAL
Intervention: Mobile phone use (Motorola GSM 8700) during a 5-minute reading task
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mobile phone use (Motorola GSM 8700) during a 6-minute exposure while speaking
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Phone call while performing a secondary task (switching attention test)
Number of subjects: 20
Study: 7606728

Group type: EXPERIMENTAL
Intervention: Deoxyspergualin (DSG) at doses of 50 mg/m2 (dl I) or 150 mg/m2 (dl II and III) administered on days 1-7.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: L6 mAb administered at a fixed dose of 200 mg/m2 on days 1-5.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Deoxyspergualin (DSG) at a starting dose of 150 mg/m2/day recommended for Phase II trials.
Number of subjects: 24
Study: 2360750

Group type: EXPERIMENTAL
Intervention: Nurse-managed intervention for smoking cessation, initiated in the hospital and maintained through telephone contact, including an 18-page manual for relapse prevention.
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Nurse-managed intervention for smoking cessation, assuming all surviving patients lost to follow-up were smoking.
Number of subjects: 173
Study: 341955

Group type: EXPERIMENTAL
Intervention: Oral beta-carotene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6758746

Group type: EXPERIMENTAL
Intervention: Prazosin 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Captopril 25 mg
Number of subjects: 10
Study: 30485123

Group type: EXPERIMENTAL
Intervention: Mindfulness-based treatment protocol
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Exercises focusing on scheduled sex and motivations for sex
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 70
Study: 29516853

Group type: EXPERIMENTAL
Intervention: Hospital EPR (n=14)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Home EPR (n=15)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Hospital EPR and Home EPR (n=14)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (n=15)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Hospital EPR
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Home EPR
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Physiotherapists' views
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Health economic analysis
Number of subjects: 58
Study: 28027630

Group type: EXPERIMENTAL
Intervention: SQ-LNSs (20 g daily)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Biscuit (3 pieces daily)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: SQ-LNSs
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Biscuit
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control
Number of subjects: 168
Study: 24271567

Group type: EXPERIMENTAL
Intervention: Instructor-guided lesson of TEE psychomotor skills with the simulator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-directed slide presentation of TEE psychomotor skills with the simulator
Number of subjects: 0
Study: 24654201

Group type: EXPERIMENTAL
Intervention: Artificial hydration (AH)
Number of subjects: 122
Study: 21063144

Group type: EXPERIMENTAL
Intervention: Perceptual learning during a 2-ball quick rotation task
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Perceptual learning
Number of subjects: 18
Study: 17690809

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg alcohol (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.7 g/kg alcohol (Experiment 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-beverage control group
Number of subjects: 0
Study: 15637138

Group type: EXPERIMENTAL
Intervention: 4-drug induction treatment with intermediate-dose cytarabine and mitoxantrone salvage treatment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Initial induction treatment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Salvage treatment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: HOX11L2 and SIL-TAL1 T-ALL
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: HOX11L2 T-ALL
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Allografting in HOX11 T-ALL patients
Number of subjects: 91
Study: 12236426

Group type: EXPERIMENTAL
Intervention: ZDV+3TC
Number of subjects: 25

Group type: COMPARATOR
Intervention: ZDV+3TC+NFV
Number of subjects: 25
Study: 10431340

Group type: EXPERIMENTAL
Intervention: Mouth rinse containing amyloglucosidase and glucose oxidase (enzyme solution)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 33
Study: 7648979

Group type: EXPERIMENTAL
Intervention: Direct contact dissolution with methyl tert‐butyl ether
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bile acid medication with or without shock‐wave lithotripsy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gallstone recurrence
Number of subjects: 60
Study: 2256740

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7404184

Group type: EXPERIMENTAL
Intervention: Multiload Cu 250
Number of subjects: 604

Group type: COMPARATOR
Intervention: Lippes loop
Number of subjects: 604
Study: 31441031

Group type: EXPERIMENTAL
Intervention: Stress Ulcer Prophylaxis (SUP)
Number of subjects: 3291

Group type: EXPERIMENTAL
Intervention: Higher SAPS II score
Number of subjects: 3291

Group type: EXPERIMENTAL
Intervention: University hospital admission
Number of subjects: 3291

Group type: EXPERIMENTAL
Intervention: Later CIB episodes
Number of subjects: 3291
Study: 28236619

Group type: EXPERIMENTAL
Intervention: Acupuncture adjunctive to zolpidem (AAZ)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Biofeedback adjunctive to zolpidem (BAZ)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (OZ)
Number of subjects: 49
Study: 25667250

Group type: EXPERIMENTAL
Intervention: MI + PI
Number of subjects: 357

Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 357

Group type: COMPARATOR
Intervention: MI only
Number of subjects: 357
Study: 24315664

Group type: EXPERIMENTAL
Intervention: 5% CO2 inhalation during hyperventilation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Room air during hyperventilation
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100% O2 during hyperventilation
Number of subjects: 12
Study: 21604824

Group type: EXPERIMENTAL
Intervention: Alcohol intervention
Number of subjects: 0
Study: 19444092

Group type: EXPERIMENTAL
Intervention: Ranolazine 1000 mg twice daily for 6 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 27
Study: 17584199

Group type: EXPERIMENTAL
Intervention: Myocardial strain imaging by tissue Doppler echocardiography
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (age-matched healthy controls)
Number of subjects: 25
Study: 15064019

Group type: EXPERIMENTAL
Intervention: 0.5Gy once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1.5Gy OD x 12 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.5Gy TDS x 12 days
Number of subjects: 24
Study: 11925292

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate 200 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate 100 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate 50 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate 25 mg
Number of subjects: 105
Study: 9819043

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa; NovoSeven)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune tolerance induction (ITI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7585167

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2696381

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 40
Study: 326349

Group type: EXPERIMENTAL
Intervention: Ornidazole 1.5 g single dose
Number of subjects: 88

Group type: COMPARATOR
Intervention: Tinidazole 2 g single dose
Number of subjects: 88
Study: 29958053

Group type: EXPERIMENTAL
Intervention: Curcumin (1 g/d)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Phospholipidated curcumin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 29030456

Group type: EXPERIMENTAL
Intervention: Percent decline in serum total homocysteine (tHcy)
Number of subjects: 16867

Group type: EXPERIMENTAL
Intervention: 20% decline in tHcy
Number of subjects: 16867

Group type: EXPERIMENTAL
Intervention: Tertiles of percent decline in tHcy
Number of subjects: 16867

Group type: EXPERIMENTAL
Intervention: Percent decline in tHcy
Number of subjects: 16867
Study: 25457567

Group type: EXPERIMENTAL
Intervention: 3D vision
Number of subjects: 46

Group type: COMPARATOR
Intervention: 2D vision
Number of subjects: 46
Study: 23295103

Group type: EXPERIMENTAL
Intervention: Referral template intervention
Number of subjects: 14
Study: 21592308

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg (evening dose) on day 3, followed by 75 mg b.i.d. on day 4
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 18495694

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) replacement
Number of subjects: 14
Study: 17000801

Group type: EXPERIMENTAL
Intervention: Remifentanil high concentration (8 ng mL(‐1))
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Remifentanil low concentration (3 ng mL(‐1))
Number of subjects: 45

Group type: COMPARATOR
Intervention: Spinal anesthesia (control group)
Number of subjects: 45
Study: 14561241

Group type: EXPERIMENTAL
Intervention: NOS3 gene polymorphisms (G894T, T‐786C)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: NOS3 gene polymorphisms (T‐786C)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: C242T CYBA polymorphism
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CA repeats
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Haplotype analysis for NOS3 polymorphisms
Number of subjects: 103
Study: 10969252

Group type: EXPERIMENTAL
Intervention: DTaP-HBV-IPV/Hib (mixed administration)
Number of subjects: 359

Group type: COMPARATOR
Intervention: DTaP-HBV-IPV + Hib (separate administration)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Both mixed and separate administration
Number of subjects: 359
Study: 9122287

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 1386029

Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg depot monthly subcutaneously)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Danazol (200 mg three times a day for 24 weeks)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 307

Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 307
Study: 6511088

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate (500 mg tablets)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Erythromycin base (500 mg enteric-coated pellets)
Number of subjects: 24
Study: 30718805

Group type: EXPERIMENTAL
Intervention: Maternal multiple micronutrient (MMN) supplementation
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Infant zinc and MMN supplementation
Number of subjects: 811
Study: 29155123

Group type: EXPERIMENTAL
Intervention: Insulin lispro low mixture (LM)
Number of subjects: 2091

Group type: COMPARATOR
Intervention: Insulin glargine (IG)
Number of subjects: 2091
Study: 26160006

Group type: EXPERIMENTAL
Intervention: Nomogram for probability-based selection for active surveillance (AS)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: PRIAS rule-based criteria
Number of subjects: 619

Group type: COMPARATOR
Intervention: Klotz rule-based criteria
Number of subjects: 619

Group type: COMPARATOR
Intervention: Johns Hopkins rule-based criteria
Number of subjects: 619
Study: 26019334

Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg) administered intravenously
Number of subjects: 32
Study: 23216417

Group type: EXPERIMENTAL
Intervention: Alcohol + diet beverage (1.97 ml/kg vodka mixed with 3.94 ml/kg diet Squirt)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Alcohol + regular beverage (1.97 ml/kg vodka mixed with 3.94 ml/kg Squirt)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cued go/no-go reaction time task performance
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Subjective measures
Number of subjects: 16
Study: 22030228

Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 49

Group type: COMPARATOR
Intervention: Butter
Number of subjects: 49

Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cheese and Butter
Number of subjects: 49
Study: 18487136

Group type: COMPARATOR
Intervention: CD-ROM feedback
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Print feedback
Number of subjects: 292
Study: 16950463

Group type: EXPERIMENTAL
Intervention: M-mode
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AM-mode
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 2DSI
Number of subjects: 25

Group type: COMPARATOR
Intervention: TDD
Number of subjects: 25
Study: 12690273

Group type: EXPERIMENTAL
Intervention: Pleconaril, 5 mg/kg/dose orally three times a day for 7 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 10714858

Group type: EXPERIMENTAL
Intervention: Fermented milk with whey protein concentrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8960577

Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 2418

Group type: COMPARATOR
Intervention: Non-aspirin treatment
Number of subjects: 2418
Study: 7932956

Group type: EXPERIMENTAL
Intervention: Quantitative Color Doppler Flow Imaging (QCDFI)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Conventional duplex scanning
Number of subjects: 224
Study: 3070414

Group type: EXPERIMENTAL
Intervention: Dialyzer re-use (6 uses of each dialyzer)
Number of subjects: 0
Study: 30319652

Group type: EXPERIMENTAL
Intervention: QBECO treatment
Number of subjects: 0
Study: 27567279

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Number of subjects: 362

Group type: COMPARATOR
Intervention: Fluorouracil plus cisplatin
Number of subjects: 362
Study: 25706882

Group type: EXPERIMENTAL
Intervention: Ozanezumab, a humanised IgG monoclonal antibody against Nogo‐A protein, administered intravenously in a first‐in‐human study.
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ozanezumab, administered intravenously, with one or two doses.
Number of subjects: 76
Study: 23154299

Group type: EXPERIMENTAL
Intervention: Tailored CR program
Number of subjects: 236

Group type: COMPARATOR
Intervention: Traditional CR program
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Both CR programs
Number of subjects: 236
Study: 22738802

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg/day
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg/day
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study: 21560631

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily + UDCA 10 mg/kg daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: Omeprazole 40 mg daily
Number of subjects: 62
Study: 18606589

Group type: EXPERIMENTAL
Intervention: econazole with polycarbophil (group A)
Number of subjects: 180

Group type: COMPARATOR
Intervention: econazole without polycarbophil (group B)
Number of subjects: 180
Study: 15976927

Group type: COMPARATOR
Intervention: Classroom-level intervention promoting social acceptance through cooperative games and teamwork-based activities.
Number of subjects: 24
Study: 11939441

Group type: EXPERIMENTAL
Intervention: Tracheal tube placement with flexible lightwand in trachea (n=40)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Tracheal tube placement with flexible lightwand in oesophagus (n=40)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Flexible lightwand-guided intubation via ILM in study 2 (n=1,000)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Protocol for correcting oesophageal intubation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Detection method using light glow and capnography
Number of subjects: 1000
Study: 10516448

Group type: EXPERIMENTAL
Intervention: MIB1 score
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: M/V index
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Papillary status
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Tumor grade
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: EGFr
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: p53
Number of subjects: 207
Study: 8818434

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study: 1408685

Group type: EXPERIMENTAL
Intervention: Nonionic contrast media (iopamidol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ionic contrast media (ioxaglate)
Number of subjects: 20
Study: 3932054

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms q.i.d.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Misoprostol 25 micrograms q.i.d.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Misoprostol 25 micrograms q.i.d. with aspirin 650 mg q.i.d.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 10
Study: 31029534

Group type: EXPERIMENTAL
Intervention: 60 μL drop of Refresh® (visit C)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No drops (visits A and B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Subjective and objective TF grading techniques
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ocular lubricants
Number of subjects: 18
Study: 28611132

Group type: EXPERIMENTAL
Intervention: Hole Implantable Collamer Lens (ICL), STAAR Surgical
Number of subjects: 351
Study: 26590023

Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy plus pharmacotherapy
Number of subjects: 199

Group type: COMPARATOR
Intervention: Collaborative care (three-session psycho-educational intervention) plus pharmacotherapy
Number of subjects: 199

Group type: COMPARATOR
Intervention: Collaborative care plus pharmacotherapy
Number of subjects: 199
Study: 24226057

Group type: EXPERIMENTAL
Intervention: Earlier ART (within 2 weeks after TB treatment initiation)
Number of subjects: 806

Group type: COMPARATOR
Intervention: Later ART (8-12 weeks after TB treatment)
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Earlier ART with CD4 <50 cells/mm³
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Earlier ART with CD4 ≥50 cells/mm³
Number of subjects: 806

Group type: COMPARATOR
Intervention: Later ART with CD4 <50 cells/mm³
Number of subjects: 806

Group type: COMPARATOR
Intervention: Later ART with CD4 ≥50 cells/mm³
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Earlier ART
Number of subjects: 806

Group type: COMPARATOR
Intervention: Later ART
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Overall TB IRIS cases
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Overall TB IRIS severity
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: IRIS management
Number of subjects: 806
Study: 22576712

Group type: EXPERIMENTAL
Intervention: Synbiotic therapy (Lactobacillus, Bifidobacterium, and galactooligosaccharides) for 8 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Synbiotic therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 20209644

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Thienopyridine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Abciximab only
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Thienopyridine and Abciximab
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 17507582

Group type: EXPERIMENTAL
Intervention: Monetary incentives for fast retrieval-based performance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Task instructions focused on speed and accuracy
Number of subjects: 0
Study: 16238791

Group type: COMPARATOR
Intervention: Dietary egg exclusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmodified healthy diet
Number of subjects: 0
Study: 11753128

Group type: COMPARATOR
Intervention: Plant extracts
Number of subjects: 0
Study: 10429851

Group type: EXPERIMENTAL
Intervention: Compat Sandoz
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Flocare Nutricia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sherwood
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mid-term evaluation
Number of subjects: 150
Study: 7590485

Group type: EXPERIMENTAL
Intervention: Intraperitoneal interferon-alpha 2b (5-30 x 10(6) units) administered on Day 1 (+/- Day 8)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous cis-platinum (75 mg/m2) plus cyclophosphamide (750 mg/m2) administered on Day 2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intraperitoneal therapy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous chemotherapy
Number of subjects: 15
Study: 1545080

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 117

Group type: COMPARATOR
Intervention: Hydralazine plus isosorbide dinitrate
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 117
Study: 3918969

Group type: EXPERIMENTAL
Intervention: 250 cGy/fraction X 4 days/week (Group B)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional dose/fraction (180‐200 cGy) X 5 days/week (Group A)
Number of subjects: 58
Study: 31083074

Group type: EXPERIMENTAL
Intervention: Pressure-free, adhesive bone conduction device
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional bone conduction device
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 13
Study: 30254071

Group type: EXPERIMENTAL
Intervention: methylation-derived neutrophil-to-lymphocyte ratio (mdNLR)
Number of subjects: 319